CCM
MYGN icon

Credo Capital Management’s Myriad Genetics MYGN Stock Holding History

Credo Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-386
Closed -$9K – 180
2013
Q3 		$9K Sell
386
-228
-37% -$6.48K 0.02% 159
2013
Q2 		$16K Buy
+614
New +$17.8K 0.01% 129

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LCG
Luxor Capital Group New York $1.43B AUM 30.88% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.28B AUM 23.15% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Credo Capital Management's MYGN Position: Q4 2013 in Review

Credo Capital Management sold out of Myriad Genetics (MYGN) in Q4 2013, closing a stake of 386 shares — an estimated $9K sold.

Credo Capital Management first reported a position in MYGN in Q2 2013 and held it in 2 quarters. The position peaked at $16K in Q2 2013. 270 funds tracked by Wall St. Rank hold MYGN as of Q4 2013.

  • Credo Capital Management reported no remaining Myriad Genetics position as of Q4 2013 after selling out during the quarter.
  • Credo Capital Management sold 386 Myriad Genetics shares in Q4 2013, an estimated $9K.
  • Credo Capital Management first reported a position in Myriad Genetics in Q2 2013 and held it in 2 quarters.
  • Credo Capital Management's Myriad Genetics position peaked at $16K in Q2 2013.
  • 270 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2013.

Based on Credo Capital Management's 13F filing for Q4 2013, filed 24 Jan 2014.